title: Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
abstract: OBJECTIVE
  To explore the association of brain-derived neurotrophic-factor (BDNF) Val66Met polymorphism with both baseline health related quality of life (HRQOL) scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
  
  
  METHODS
  Patients with major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks. The HRQOL was measured with the Medical Outcomes Study Short Form-36 (SF-36) at baseline and at 6th week. Patients were genotyped for Val66Met polymorphism of BDNF gene.
  
  
  RESULTS
  There was a significant association between social function (SF) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had better SF (compared with Val/Val P = 0.004; compared with Val/Met P = 0.005). A significant association was found between improvement in SF and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in SF (compared with Val/Val P = 0.010; compared with Val/Met P = 0.001). Similar association was found between improvement in mental component summary (MCS) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in MCS (compared with Val/Val P = 0.066; compared with Val/Met P = 0.006).
  
  
  CONCLUSIONS
  These results indicate that there may be association between BDNF Val66Met polymorphism and both baseline HRQOL (SF) scores and improvement in HRQOL (SF, MCS) scores in Chinese major depressive patients treated with fluoxetine.
authors.affiliation: Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
authors.forename: Yan-Feng
authors.initials: YF
authors.lastname: Zou
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
authors.forename: Xiao-Liang
authors.initials: XL
authors.lastname: Feng
authors.forename: Bin-Yan
authors.initials: BY
authors.lastname: Wang
authors.forename: Tong-Hua
authors.initials: TH
authors.lastname: Zang
authors.forename: Xin
authors.initials: X
authors.lastname: Yu
authors.forename: Jing
authors.initials: J
authors.lastname: Wei
authors.forename: Zhong-Chun
authors.initials: ZC
authors.lastname: Liu
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Ming
authors.initials: M
authors.lastname: Tao
authors.forename: Hui-Chun
authors.initials: HC
authors.lastname: Li
authors.forename: Ke-Qing
authors.initials: KQ
authors.lastname: Li
authors.forename: Jian
authors.initials: J
authors.lastname: Hu
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.forename: Ke-Rang
authors.initials: KR
authors.lastname: Zhang
authors.forename: Dong-Qing
authors.initials: DQ
authors.lastname: Ye
authors.forename: Xi-Ping
authors.initials: XP
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019943:Amino Acid Substitution; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D002681:China; D015331:Cohort Studies; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D005787:Gene Frequency; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011788:Quality of Life / Q000523:psychology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012919:Social Behavior; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors